Neurol India Home 
 

ORIGINAL ARTICLE
Year : 2018  |  Volume : 66  |  Issue : 1  |  Page : 65--70

Etiologic spectrum and prognosis in noncompressive acute transverse myelopathies: An experience of 80 patients at a tertiary care facility

Shuchit Pandey1, Ravindra K Garg1, Hardeep S Malhotra1, Amita Jain2, Kiran P Malhotra3, Neeraj Kumar1, Rajesh Verma1, Praveen K Sharma1,  
1 Department of Neurology, King George Medical University, Lucknow, Uttar Pradesh, India
2 Department of Microbiology, King George Medical University, Lucknow, Uttar Pradesh, India
3 Department of Pathology, Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

Correspondence Address:
Dr. Ravindra K Garg
Department of Neurology, King George Medical University, Lucknow - 226 003, Uttar Pradesh
India

Abstract

Introduction: We evaluated the spectrum of acquired demyelinating and inflammatory disorders in patients presenting with an acute transverse myelopathy. We also studied differences between an acute idiopathic transverse myelitis and myelitis resulting from other etiologies. Materials and Methods: Eighty consecutive patients with acute transverse myelopathy were included. At inclusion, clinical profile, serum and cerebrospinal fluid parameters, brain and spinal cord magnetic resonance imaging, and visual evoked potentials were obtained. All patients were given methylprednisolone therapy. Patients were followed up for 6 months. Outcome was assessed using modified Barthel index. A modified Barthel index score of ≤12 indicated a poor prognosis. Results: Majority (n = 49; 61.25%) of patients had idiopathic acute transverse myelitis. Eleven cases had neuromyelitis optica spectrum disorders (8 had anti-aquaporin antibody positivity). Multiple sclerosis was diagnosed in 7 cases. Eight cases had infectious or parainfectious myelitis. Longitudinally extensive transverse myelitis was noted in 66 (82.5%) patients. Seventeen patients had abnormalities in the brain. Majority of patients improved following methylprednisolone therapy. On univariate analysis, delay in administering methylprednisolone therapy, poor modified Barthel index at discharge, and extensive cord involvement were associated with severe residual disability. On multivariate analysis, delayed initiation of methylprednisolone was identified as a poor prognostic factor. Conclusion: A variety of inflammatory, infective, demyelinating, and autoimmune disorders present with acute transverse myelopathy. Early institution of methylprednisolone reduces the disability in these patients.



How to cite this article:
Pandey S, Garg RK, Malhotra HS, Jain A, Malhotra KP, Kumar N, Verma R, Sharma PK. Etiologic spectrum and prognosis in noncompressive acute transverse myelopathies: An experience of 80 patients at a tertiary care facility.Neurol India 2018;66:65-70


How to cite this URL:
Pandey S, Garg RK, Malhotra HS, Jain A, Malhotra KP, Kumar N, Verma R, Sharma PK. Etiologic spectrum and prognosis in noncompressive acute transverse myelopathies: An experience of 80 patients at a tertiary care facility. Neurol India [serial online] 2018 [cited 2020 Oct 26 ];66:65-70
Available from: https://www.neurologyindia.com/text.asp?2018/66/1/65/222877


Full Text



Transverse myelitis is a pathogenetically heterogeneous inflammatory disorder presenting with acute or subacute spinal cord dysfunction. Clinically, it is characterized by a triad of motor, sensory, bladder and bowel abnormalities. Magnetic resonance imaging (MRI) shows a hyperintense spinal cord lesion extending over several cord segments. Acute transverse myelitis is either an isolated inflammatory phenomenon or a manifestation of a widespread multifocal central nervous system demyelinating disorder such as acute disseminated encephalomyelitis, multiple sclerosis, or neuromyelitis optica. Several rheumatological diseases such as systemic lupus erythematosus, Sjogren's syndrome, para-infectious myelitis, spinal cord infarct, and infectious myelitis can present with acute transverse myelopathy.[1],[2]

Acute transverse myelitis, depending on the extent of spinal cord involvement (on magnetic resonance imaging [MRI] appearing as a a hyperintense lesion), can be categorized into a long-segment (equal to or more than 3 vertebral segments) or short segment (less than 3 vertebral segments) myelitis. Long-segment myelitis, also known as longitudinally extensive transverse myelitis, is a devastating disorder characteristically seen in neuromyelitis optica spectrum disorders. Small-segment myelitis and asymmetric spinal cord lesions are characteristically seen on MRI in multiple sclerosis. Idiopathic acute transverse myelitis is the most common cause of acute myelitis in India. Idiopathic acute transverse myelitis is characterized by inflammatory changes in the cerebrospinal fluid and demonstration of absence of a specific cause such as multiple sclerosis, neuromyelitis optica spectrum disorders, acute disseminated encephalomyelitis, or a connective tissue disease.[3],[4]

The exact incidence and prevalence of acute transverse myelitis in India, particularly in North India, is not known. In South India, the prevalence of multiple sclerosis was noted as 8.3/100,000, and the prevalence of neuromyelitis optica spectrum disorders was 2.6/100,000 among all demyelinating disorders.[5],[6]

In this study, we evaluated the spectrum of acquired demyelinating and inflammatory disorders. At initial presentation, we tried to establish a differential diagnosis among various causes of acute transverse myelopathies. We evaluated the differences in the clinical spectrum of disorders having short-segment or long-segment transverse myelitis. The clinical, immunological, and radiological factors determining the prognosis were also evaluated.

 Materials and Methods



This prospective study was conducted in the Department of Neurology at King George's Medical University Uttar Pradesh, Lucknow, India, between July 2013 and January 2016. The study was approved by the Institutional Ethics Committee. A written informed consent was obtained from patients or their legal guardians.

Consecutive patients presenting with acute transverse myelopathy (motor and sensory deficit, sphincteric involvement, and a well-defined upper sensory segmental level) were enrolled.

Neuroimaging

The patients, after their inclusion in the study, were subjected to a cranial and spinal MRI. The MRI protocol included conventional T1-weighted images, T2-weighted images, fluid-attenuated inversion recovery (FLAIR) images, diffusion-weighted images (DWI) with apparent diffusion coefficient (ADC) maps and contrast-enhanced T1-weighted images. In spinal MRI, we noted the number of lesions, their extent, and localization in the sagittal (cervical, dorsal, and lumbar); section while in the axial sections centromedullary versus a peripheral location, cord edema, and the changes visible following gadolinium-contrast administration were noted. Longitudinally, extensive transverse myelitis was diagnosed if a patient had spinal lesions extending ≥ 3 vertebral segments. In cranial MRI, we focussed on the periventricular, cortical, and infratentorial changes.

Laboratory findings

Patients were subjected to a complete hemogram, liver function tests, kidney function tests, serum electrolytes, chest X-ray, urine analysis, and electrocardiogram. Serological tests for hepatitis B, hepatitis C, and human immunodeficiency virus were performed. Patients were also tested for antinuclear antibodies, anti-aquaporin 4 antibodies, and vasculitis (anti-proteinase 3 and anti-myeloperoxidase antibodies).

Lumbar puncture was performed in all patients. Cerebrospinal fluid (CSF) was examined for protein, cells, and sugar. CSF specimens were evaluated for herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein Barr virus, dengue virus, mumps virus, and polymerase chain reaction for tuberculosis.

Visual evoked potential

At inclusion, visual evoked potential was performed for every included patient.

Treatment and follow-up

Patients were treated with intravenous methylprednisolone (20 mg/kg body weight per day; a maximum of 1 g per day) for 5 days. Patients were followed up for 6 months. Disability was assessed using the modified Barthel activities of daily living index, a 20-point scoring system.[7] A good outcome was defined as a modified Barthel index score of >12; and, a poor outcome was defined as a modified Barthel index score of ≤12. A relapse was considered when there was appearance of new symptoms or worsening of an existing symptom along with an objective documentation. It was ensured that clinical worsening occurred in the absence of fever and lasted for at least 24 hours.

Definitions

The diagnosis of idiopathic transverse myelitis was made based on the criteria given by the Transverse Myelitis Consortium Working Group [Table 1].[8]{Table 1}

The diagnosis of multiple sclerosis was made on the basis of the revised McDonald criteria.[9] Neuromyelitis optica spectrum disorders were classified according to the International Consensus Diagnostic Criteria For Neuromyelitis Optica Spectrum Disorders.[10] Parainfectious and infectious myelitis were diagnosed if there was a serological correlate of a recent infection. Systemic lupus erythematosus and Sjögren's syndrome were diagnosed with the help of appropriate diagnostic criteria.[11],[12]

Statistical analysis

Statistical analysis was performed using the Statistical Package for the Scoial Sciences (SPSS) software (version 16.0; Chicago, LA). All categorical variables were expressed as percentages, and continuous variables were expressed as mean ± standard deviation. Categorical variables were compared using chi-square test. Mean values were compared using independent-sample t-test. Odds ratio and 95% confidence interval were calculated. Variables found to be significantly associated with a poor outcome were further subjected to binary logistic regression. P values < 0.05 were taken as significant, with all analyses being two-tailed.

 Results



We included 80 consecutive patients suffering from acute transverse myelopathy. The algorithm and outcomes of the study are depicted in [Figure 1]. The initial clinical, laboratory, and neuroimaging characteristics, and outcome of the included patients are presented in [Table 2].{Figure 1}{Table 2}

Majority (49, 61.25%) of the patients had idiopathic acute transverse myelitis. The next major group of disorders was neuromyelitis optica spectrum disorders. Out of 11 (13.75%) cases of neuromyelitis optica spectrum disorders, 8 (86.5%) were anti-aquaporin IgG antibody positive. Multiple sclerosis was diagnosed in 7 (8.75%) cases. Eight cases had either infectious or parainfectious etiology. Among the cases with infectious myelitis, 3 cases had evidence of tuberculosis in the CSF. In 2 patients, a viral etiology was identified (Herpes simplex virus-1 and dengue). Two patients had parainfectious myelitis; one occurred after Herpes zoster and the other occurred after mumps. Three patients had systemic lupus erythematosus whereas 2 patients had Sjögren's syndrome.

Visual abnormalities (visual complaints and/or an abnormal visual evoked potential) were significantly less frequent in patients with idiopathic acute transverse myelitis compared with other acute myelopathies [Table 2]. Visual complaints were not reported by any patient with idiopathic transverse myelitis; however, it was seen in 12.9% patients with other myelopathies (P = 0.020). On comparing the visual evoked potential parameters in these groups, abnormal visual evoked potential was more common in other varieties of myelopathies (38.7%) compared to idiopathic transverse myelitis [10.2%] (P = 0.004, odd's ratio [OR] = 5.558, 95% confidence interval [CI] 1.718–17.97). Abnormal visual evoked potential was most commonly seen in patients with neuromyelitis optica (P< 0.001).

Short-segment myelitis versus longitudinally-extensive myelitis

A comparison between clinical, laboratory, and neuroimaging characteristics of longitudinally-extensive transverse myelitis and short-segment myelitis is shown in [Table 3]. Involvement of the spinal cord with longitudinally-extensive myelitis vis-a-vis short-segment myelitis and neuromyelitis optica with aquaporin 4 antibody positivity in individual cases is depicted in [Figure 2] and [Figure 3], respectively.{Figure 2}{Figure 3}{Table 3}

Majority (n = 66, 82.5%) of our patients had longitudinally-extensive transverse myelitis. Eleven patients had cervical myelitis, 32 patients had cervicothoracic myelitis, 24 patients had thoracic myelitis, and 13 patients had whole cord myelitis. Centromedullary involvement was more frequent in the idiopathic transverse myelitis group. Seventeen patients had an abnormal brain MRI; 7 patients with periventricular changes were later diagnosed as having multiple sclerosis [Table 3].

The most common etiology of longitudinally-extensive transverse myelitis was idiopathic transverse myelitis (40/66, 60.6%). Neuromyelitis optica spectrum disorders (10/66, 15.2%) was the next frequent category. Infectious/parainfectious causes were detected in 10.6% (7/66) of the patients. In 14 patients with short segment myelitis, 9 (64.3%) patients had idiopathic transverse myelitis and 3 (21.4%) had multiple sclerosis. A young age, female gender, centromedullary involvement, and cord swelling on MRI were significantly more common in patients with longitudinally-extensive transverse myelitis [Table 4].{Table 4}

Follow up at 6 months

After 6 months, 57 (71.25%) patients had a modified Barthel index score >12 whereas 23 (28.75%) patients had a modified Barthel index score ≤12 (including 7 deaths).

Predictors of outcome

On univariate analysis, delayed methylprednisolone therapy (P = 0.001; CI = −7.515 to − 1.980), a poor modified Barthel index at discharge (P< 0.001; CI = 1.844–4.614), higher number of segments involved (P = 0.005; CI = −6.930 to − 1.308), and whole cord involvement (P = 0.039) were factors associated with a poor outcome. On multivariate analysis, delayed methylprednisolone therapy was the lone independent factor associated with a poor outcome.

 Discussion



In majority of our patients with acute transverse myelopathies, the diagnosis of idiopathic acute transverse myelitis was made. We tried to differentiate acute idiopathic transverse myelitis from other causes of acute transverse myelopathy at the first presentation. We noted that visual symptoms, abnormal visual evoked potentials, and brain involvement indicated an alternative diagnosis, taking into context an acute idiopathic transverse myelitis. Patients with multiple sclerosis and neuromyelitis optica spectrum disorders more frequently had brain lesions on MRI. On neuroimaging, brain lesions in multiple sclerosis and neuromyelitis optica spectrum disorders may largely look similar but hypothalamic, periaqueductal gray, and area postrema lesions are more suggestive of the latter. In multiple sclerosis, juxtacortical, U-fibre lesions, or Dawson's finger abnormalities are more frequent.[13],[14]

In neuromyelitis optica spectrum disorders and idiopathic acute transverse myelitis, the inflammatory process usually affects greater than three vertebral segments.[1],[2]

Even though a cutoff of 3 vertebral segments for longitudinally-extensive transverse myelitis is considered, our observations indicate that not all patients demonstrating greater than 3 vertebral segment involvement have a poor outcome. As per our data regarding absolute numbers, a cutoff median value of less than 7 segments and greater than 14 segments (P = 0.007) predicts a good and poor outcome, respectively.

We noted that, in 5 patients, who had longitudinally-extensive myelitis, a causative organism (tuberculosis, Herpes simplex virus, and dengue virus) was detected. We suggest that, if there has been a recent systemic infection or if cerebrospinal fluid (CSF) pleocytosis is present, serum and CSF should be subjected to an estimation of infective agents. The list may be long but some important ones known to present with acute transverse myelopathies such as Herpes simplex, cytomegalovirus, Varicella zoster, mumps, dengue viruses, syphilis, tuberculosis and Lyme borreliosis should be carefully looked for.[1],[2]

Do patients of idiopathic acute transverse myelitis convert to multiple sclerosis? In our series, we noted that during the 6 months of follow-up, approximately 9% of the patients converted to multiple sclerosis. A retrospective review from Spain had noted that 13% (11/87) of patients converted to multiple sclerosis after a median follow-up of 2.9 years. Early-age onset of symptoms was significantly associated with the conversion to multiple sclerosis. In this study, 9.4% of the patients with idiopathic acute transverse myelitis were unable to walk unassisted at the end of the follow-up. Urinary sphincteric dysfunction and longitudinally-extensive transverse myelitis were associated with a poor outcome.[15]

It, therefore, becomes pertinent to follow patients with idiopathic transverse myelitis to look for recurrences and define an appropriate diagnosis. In our study, the rate of conversion to multiple sclerosis may increase with a longer follow-up.

We noted that the disability status in our patients was not influenced by the type of demyelinating disorder and a majority of patients improved following methylprednisolone therapy. A delayed initiation of methylprednisolone therapy, a significant initial disability, and an extensive cord involvement irrespective of the etiology, were associated with severe residual disability. We argue that patients with extensive cord involvement need more aggressive treatment such as plasmapheresis and/or intravenous immunoglobulins at the outset. The role of immunosuppressive treatment also needs to be investigated.[16]

A limitation of our study was that we did not use Spinal Cord Independence Measure scale. It is a comprehensive rating scale that measures the ability of patients with spinal cord lesions to perform everyday tasks. Spinal Cord Independence Measure scale measures the abilities of self-care (feeding, grooming, bathing, and dressing), respiration and sphincter management, and a patient's mobility abilities (bed and indoors/outdoors transfers). We recommend that Spinal Cord Independence Measure should be used along with the modified Barthel Index in future evaluations.[17]

In conclusion, a variety of inflammatory, infective, demyelinating, and autoimmune disorders can present with acute transverse myelitis. Visual symptoms, brain involvement, and extensive spinal cord involvement indicate a diagnosis other than acute idiopathic transverse myelitis. Methylprednisolone, early in the course of the disease, helps in improving disability.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1West TW, Hess C, Cree BA. Acute transverse myelitis: Demyelinating, inflammatory, and infectious myelopathies. Semin Neurol 2012;32:97-113.
2Frohman EM, Wingerchuk DM. Clinical practice. Transverse myelitis. N Engl J Med 2010;363:564-72.
3Pekcevik Y, Mitchell CH, Mealy MA, Orman G, Lee IH, Newsome SD, et al. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Mult Scler 2016;22:302-11.
4Jacob A, Weinshenker BG. An approach to the diagnosis of acute transverse myelitis. Semin Neurol 2008;28:105-20.
5Singhal BS, Advani H. Multiple sclerosis in India: An overview. Ann Indian Acad Neurol 2015;18(Suppl 1):S2-5.
6Pandit L, Kundapur R. Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Mult Scler 2014;20:1651-3.
7Collin C, Wade DT, Davies S, Horne V. The Barthel ADL Index: A reliability study. Int Disabil Stud 1988;10:61-3.
8Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002;59:499-505.
9Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
10Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-89.
11Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
12Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
13Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder: An international update. Neurology 2015;84:1165-73.
14Tackley G, Kuker W, Palace J. Magnetic resonance imaging in neuromyelitis optica. Mult Scler 2014; 20:1153-64.
15Cobo Calvo A, Mañé Martínez MA, Alentorn-Palau A, Bruna Escuer J, Romero Pinel L, Martínez-Yélamos S. Idiopathic acute transverse myelitis: Outcome and conversion to multiple sclerosis in a large series. BMC Neurol 2013;13:135.
16Bevan CJ, Cree BA. Fulminant demyelinating diseases of the central nervous system. Semin Neurol 2015;35:656-66.
17Catz A, Itzkovich M, Agranov E, Ring H, Tamir A. SCIM-spinal cord independence measure: A new disability scale for patients with spinal cord lesions. Spinal Cord 1997;35:850-6.